FI112483B - Förfarande för framställning av terapeutiskt användbara 3-[2-[4-(6-fluor-1,2-bensioxazol-3-yl) -1-piperidinyl]etyl]-2-alkylpyrimidin-4-onderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara 3-[2-[4-(6-fluor-1,2-bensioxazol-3-yl) -1-piperidinyl]etyl]-2-alkylpyrimidin-4-onderivat

Info

Publication number
FI112483B
FI112483B FI962155A FI962155A FI112483B FI 112483 B FI112483 B FI 112483B FI 962155 A FI962155 A FI 962155A FI 962155 A FI962155 A FI 962155A FI 112483 B FI112483 B FI 112483B
Authority
FI
Finland
Prior art keywords
pct
novel compounds
date
benzioxazol
alkylpyrimidin
Prior art date
Application number
FI962155A
Other languages
English (en)
Finnish (fi)
Other versions
FI962155A0 (sv
FI962155A (sv
Inventor
Jan Vandenberk
Ludo Edmond Josephine Kennis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI962155A0 publication Critical patent/FI962155A0/sv
Publication of FI962155A publication Critical patent/FI962155A/sv
Application granted granted Critical
Publication of FI112483B publication Critical patent/FI112483B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI962155A 1993-11-23 1996-05-22 Förfarande för framställning av terapeutiskt användbara 3-[2-[4-(6-fluor-1,2-bensioxazol-3-yl) -1-piperidinyl]etyl]-2-alkylpyrimidin-4-onderivat FI112483B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203270 1993-11-23
PCT/EP1994/003804 WO1995014691A1 (en) 1993-11-23 1994-11-16 NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES

Publications (3)

Publication Number Publication Date
FI962155A0 FI962155A0 (sv) 1996-05-22
FI962155A FI962155A (sv) 1996-05-22
FI112483B true FI112483B (sv) 2003-12-15

Family

ID=8214180

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962155A FI112483B (sv) 1993-11-23 1996-05-22 Förfarande för framställning av terapeutiskt användbara 3-[2-[4-(6-fluor-1,2-bensioxazol-3-yl) -1-piperidinyl]etyl]-2-alkylpyrimidin-4-onderivat

Country Status (14)

Country Link
US (1) US5688799A (sv)
EP (1) EP0730594B1 (sv)
JP (1) JP3553951B2 (sv)
AT (1) ATE184281T1 (sv)
AU (1) AU687940B2 (sv)
CA (1) CA2175372C (sv)
DE (1) DE69420579T2 (sv)
DK (1) DK0730594T3 (sv)
ES (1) ES2137486T3 (sv)
FI (1) FI112483B (sv)
GR (1) GR3031500T3 (sv)
RU (1) RU2126406C1 (sv)
SI (1) SI0730594T1 (sv)
WO (1) WO1995014691A1 (sv)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO2004009591A1 (en) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. A process for the preparation of antipsychotic risperidone
AU2003256006A1 (en) * 2002-08-30 2004-03-19 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
HUP0401379A3 (en) * 2004-07-08 2006-04-28 Richter Gedeon Vegyeszet Process for the preparation of risperidon
EP1791839B1 (en) * 2004-09-09 2015-06-10 Janssen Pharmaceutica NV Preparation of 9-hydroxy-3-(2-hydroxyethyl)-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one and crystalls thereof
HUP0402163A2 (en) * 2004-10-25 2006-05-29 Richter Gedeon Vegyeszet Process for the preparation of risperidone
DE07811307T1 (de) * 2006-08-14 2008-07-31 Teva Pharmaceutical Industries Ltd. Amorphe und Kristlline Formen von 9-Hydroxyrisperidon (Paliperidon)
DE202007018473U1 (de) 2006-08-14 2008-08-07 Teva Pharmaceutical Industries Ltd. 9-Hydroxy-Risperidon (Paliperidon)
US7820816B2 (en) * 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
US8071767B2 (en) * 2007-01-08 2011-12-06 Actavis Group Ptc Ehf Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride
US20080171876A1 (en) * 2007-05-10 2008-07-17 Santiago Ini Pure paliperidone and processes for preparing thereof
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
WO2009015828A1 (en) * 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
WO2009056990A2 (en) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Paliperidone polymorphs
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
WO2009044413A2 (en) * 2007-10-05 2009-04-09 Matrix Laboratories Limited Improved process for preparing paliperidone, novel polymorphic forms of the same and process thereof
WO2009070306A1 (en) * 2007-11-27 2009-06-04 Teva Pharmaceutical Industries Ltd. Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone)
AR069621A1 (es) * 2007-12-10 2010-02-03 Synthon Bv Sintesis de paliperidona
TWI385157B (zh) * 2008-01-16 2013-02-11 Scinopharm Taiwan Ltd 用於製備帕潘立酮（ｐａｌｉｐｅｒｉｄｏｎｅ）之新穎中間體
BRPI0905938A2 (pt) * 2008-02-05 2018-05-29 Watson Pharma Private Ltd processo para preparação de 3-(2 cloroetil)- 2- metil hidróxi- 4h-pirido [l, 2-a] pirimidina-4- ona, de 3- (2-cloroetil)-6,7,8,9- tetraidro 9- hidróxil-2-metil-4h-pirido[1,2-a]pirimidina-4-ona, de 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-il)-1-piperidinil]etil]-6,7,8,9-tetaidro-9-hidróxi-2-metil-4h-pirido[1,2-a]pirimidina-4-ona bruta, e processo para a purificação da paliperidona
EP2280967A2 (en) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
ES2625323T3 (es) 2008-05-29 2017-07-19 Inke, S.A. Proceso para preparar paliperidona e intermedios de la misma
WO2010004578A2 (en) 2008-06-16 2010-01-14 Msn Laboratories Limited Novel and improved processes for the preparation of paliperidone
EP2318405A2 (en) * 2008-07-11 2011-05-11 Synthon B.V. Paliperidone ketone
EP2321311B1 (en) * 2008-07-11 2012-09-19 Synthon B.V. Synthesis of paliperidone
WO2010064134A2 (en) * 2008-12-05 2010-06-10 Cadila Pharmaceuticals Ltd. Process of synthesis of paliperidone
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
US20120100188A1 (en) 2009-05-28 2012-04-26 Actavis Group Ptc Ehf Solid state forms of paliperidone salts and process for the preparation thereof
WO2011030224A2 (en) 2009-09-10 2011-03-17 Actavis Group Ptc Ehf Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
WO2011073997A2 (en) 2009-12-14 2011-06-23 Cadila Healthcare Limited Process for preparing paliperidone and pharmaceutically acceptable salts thereof
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
CN103387575A (zh) * 2013-07-22 2013-11-13 江苏万特制药有限公司 帕潘立酮的制备方法及其关键中间体
KR101867988B1 (ko) * 2016-11-02 2018-06-15 주식회사 엔지켐생명과학 팔리페리돈 중간체 및 이를 이용한 팔리페리돈의 제조방법
CN115260190A (zh) * 2022-08-30 2022-11-01 南开大学 一种帕利哌酮前药、制剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones

Also Published As

Publication number Publication date
DK0730594T3 (da) 2000-03-27
AU1065495A (en) 1995-06-13
JPH09505574A (ja) 1997-06-03
FI962155A0 (sv) 1996-05-22
JP3553951B2 (ja) 2004-08-11
RU2126406C1 (ru) 1999-02-20
FI962155A (sv) 1996-05-22
GR3031500T3 (en) 2000-01-31
EP0730594B1 (en) 1999-09-08
EP0730594A1 (en) 1996-09-11
DE69420579T2 (de) 2000-04-27
AU687940B2 (en) 1998-03-05
CA2175372A1 (en) 1995-06-01
WO1995014691A1 (en) 1995-06-01
SI0730594T1 (en) 1999-12-31
ATE184281T1 (de) 1999-09-15
DE69420579D1 (de) 1999-10-14
ES2137486T3 (es) 1999-12-16
US5688799A (en) 1997-11-18
CA2175372C (en) 2006-02-21

Similar Documents

Publication Publication Date Title
FI112483B (sv) Förfarande för framställning av terapeutiskt användbara 3-[2-[4-(6-fluor-1,2-bensioxazol-3-yl) -1-piperidinyl]etyl]-2-alkylpyrimidin-4-onderivat
LU91362I2 (fr) Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
FI900085A (sv) Förfarande för framställning av terapeutiskt användbara N-(pyrimidin- och kondenserad pyrimidin-4-on)etyl-piperidin- och piperatzinderivat
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
CA2203274A1 (en) Apolipoprotein-b synthesis inhibitors
MY132062A (en) Apolipoprotein-b synthesis inhibitors
FI911885A0 (sv) Förfarande för framställning av terapeutiskt användbara 2,9-disubstituerade 3-/2-/4-(6-fluor-1,2-bensisoxazol-3-yl)-piperidinyl/etyl/-4H-pyrido/1,2-a/pyrimidin-4-oner
IL125982A0 (en) 2-(arylphenyl) amino-imidazoline derivatives
NO167803C (no) Analogifremgangsmaate til fremstilling av terapeutiskordskilleaktive n-(4-piperidinyl)bicyklisk kondenserte 2-imidazolaminderivater.
ES8100263A1 (es) Procedimiento para preparar un derivado de acido 1-bencil-1,2,5,6-tetrahidropiridina-3-carboxilico
NO176608C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater